ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
2 hedge funds and large institutions have $10.4K invested in ELITE PHARMACEUTICAL in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
73% more capital invested
Capital invested by funds: $6K → $10.4K (+$4.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
+$5K |
Top Sellers
ELI Hedge Fund Activity: Q2 2018 in Review
2 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2018, worth a combined $10.4K — up 73% from $6K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Highlander Capital Management, opening a new position worth an estimated $5K.
- 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2018, up from 1 in Q1 2018.
- Funds reported $10.4K of ELITE PHARMACEUTICAL stock for Q2 2018, up 73% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q2 2018 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q2 2018 was Highlander Capital Management, an estimated $5K added.
Based on aggregated 13F filings for Q2 2018.